Search research articles
Contact Us
Filters
Showing results (81-90 of 87) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
C Baldini, E Charton, E Schultz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J M Michot, C Bigenwald, S Champiat, et al.
ESMO Open
|
August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
E Charton, C Baldini, Y Fayet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
ESMO Open
|
August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
M Simonelli, E Garralda, F Eskens, et al.
Bone Marrow Transplantation
|
December 8, 2015
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
A Necchi, R Miceli, M Bregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 87) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
C Baldini, E Charton, E Schultz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J M Michot, C Bigenwald, S Champiat, et al.
ESMO Open
|
August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
E Charton, C Baldini, Y Fayet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
ESMO Open
|
August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
M Simonelli, E Garralda, F Eskens, et al.
Bone Marrow Transplantation
|
December 8, 2015
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
A Necchi, R Miceli, M Bregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 9